Stocktoria
Gain Therapeutics, Inc. GANX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-03-18
Chart by TradingView
4/9
Piotroski F — financial health
-7.1
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | $55,180 | $132,640 | $164,994 |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M | -$13.8M |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M | -$13.9M |
| Operating cash flow | -$18.5M | -$18.9M | -$18.9M | -$14.7M | -$12.4M |
| Free cash flow | — | — | — | — | -$12.5M |
| Total assets | $22.8M | $12.1M | $18.6M | $24.1M | $39.0M |
| Total liabilities | $4.3M | $4.8M | $6.0M | $5.2M | $4.2M |
| Shareholders' equity | $18.6M | $7.3M | $12.6M | $18.9M | $34.8M |
| Ratios | |||||
| Operating margin | — | — | -40328.3% | -13402.5% | -8379.8% |
| Net margin | — | — | -40354.3% | -13262.0% | -8418.9% |
| FCF margin | — | — | — | — | -7551.7% |
| Return on assets | -88.4% | -168.4% | -119.7% | -73.0% | -35.6% |
| Return on equity | -108.6% | -278.1% | -177.0% | -93.2% | -39.9% |
| Debt / equity | 0.02× | 0.04× | 0.04× | 0.03× | 0.02× |
| Current ratio | 6.63 | 2.97 | 3.59 | 5.11 | 14.78 |
| Revenue growth | — | — | -58.4% | -19.6% | 471.3% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| GREENLIGHT CAPITAL INC | 588,410 | $1.9M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.1 (distress)
- Working capital / assets 0.828
- Retained earnings / assets -3.558
- EBIT / assets -0.82
- Equity / liabilities 4.364
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001819411 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.